These results were confirmed in a multivariate Cox regression model adjusted for age, KPS, therapy, resection efficiency and MGMT status where CD66bhigh/PLOD2high patients had a significantly increased hazard ratio compared to the other groups of GBM patients (HR = 1.703, CI [95%] = 1.067–2.720, p = 0.026) (Figure 6F). The gene discussed is MGMT; the disease is glioblastoma.